
With increasing participation in aquatics athletics at the youth, amateur, and professional levels, it is critical to provide sport and venue-specific emergency action plans (EAP) to ensure safe participation for athletes with and without cardiovascular disease. Current EAPs are typically geared toward land-based sports and do not address major aquatic-specific obstacles including identification of emergency, extraction, automated external defibrillator availability, emergency medical services access, and transport to hospital. This document provides guidance on creating EAP for aquatic athletes based on sport type and venue (pool-based, open-water immersion, and open-water adjacent) with guidance and proposed solutions for each. It also highlights the growing need for detailed aquatic EAPs to ensure safe athlete participation for water-based athletes. Finally, we call upon leaders in aquatic sports to involve all stakeholders and consider implementing more structured training in addition to basic life support, cardiopulmonary resuscitation, and first-aid to maximize aquatic athlete safety.
Background: Anemia and iron deficiency (ID) are highly prevalent among patients hospitalized for heart failure (HHF). Their prognostic contributions in the acute setting, particularly across kidney function, remain incompletely understood. Objectives: We investigated the association of anemia, transferrin saturation (TSAT), and ID according to kidney function, with postdischarge outcomes in HHF patients. Methods: Consecutive HHF patients enrolled in the OPPORTUNITIES registry with available hemoglobin and TSAT at discharge. The primary endpoint was HF-free survival, a composite of all-cause death, urgent heart transplantation, heart failure (HF) hospitalization, and urgent emergency department referral for HF worsening at 12 months. Adjusted Cox regression models were applied. Results: A total of 454 HHF patients were included. The median age was 77 (69-83); 37.9% were women, and 55% of patients were anemic. Anemic patients were older and exhibited a greater burden of comorbidities. Hemoglobin and TSAT showed a modest positive correlation overall (rho = 0.276, P < 0.001), which disappeared in patients with estimated glomerular filtration rate <30 mL/min/1.73 m 2 . Lower hemoglobin was independently associated with a higher risk (adjusted HR: 0.82; 95% CI: 0.75-0.91; P < 0.001), whereas TSAT was not independently predictive. A significant interaction between hemoglobin and renal function was observed ( P = 0.025), indicating that the hemoglobin effect varied according to kidney function. Among ID definitions, only TSAT <20% independently identified patients at an increased risk (HR: 1.44; 95% CI: 1.03-2.03; P = 0.035). Conclusions: In HHF patients, the prognostic relevance of anemia varies according to renal function. TSAT <20% was the only ID definition independently associated with adverse outcomes.
Background The number of sites performing transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation (SMR) has increased. Despite concerns that low-volume sites may have worse outcomes, data are limited on the association between site volume and TEER outcomes. Objectives This study aimed to assess the association between site volume and mitral TEER outcomes in SMR. Methods The COAPT PAS (COAPT Post-Approval Study) included patients with SMR who underwent TEER with the MitraClip device from March 2019 to September 2020 following Food and Drug Administration approval. Sites were categorized by number of patients treated: low (≤25), medium (25-50), and high (>50). Results Of 5,000 patients, 2,632 were from low-, 1,527 from medium-, and 841 from high-volume sites. High-volume sites treated sicker patients with higher Society of Thoracic Surgeons scores and prior heart failure hospitalization rates. Procedures at low-volume sites had similar device implant rates (low: 97%, medium: 99%, high: 98%), used fewer number of clips (low: 1.4 ± 0.6, medium: 1.5 ± 0.6, high: 1.6 ± 0.7 clips, P < 0.001), and had longer device (low: 68 ± 55, medium: 56 ± 53, high: 57 ± 42 min, P < 0.001) and procedure times (low: 153 ± 67, medium: 131 ± 59, high: 128 ± 56 min, P < 0.001). Technical success was comparable (low: 93%, medium: 94%, high: 95%, P = 0.92). MR reduction to ≤2+ and ≤1+ was also similar. There was no difference in heart failure hospitalization (low: 19%, medium: 18%, high: 20%, P = 0.50) or all-cause mortality (low: 23%, medium: 21%, high: 20%, P = 0.27). Conclusions Technical success, MR reduction, and 1-year clinical outcomes were comparable across volume strata during the early adoption phase, without significant differences between low- and high-volume centers.
Background The 2026 American College of Cardiology (ACC)/American Heart Association (AHA)/Multisociety Guideline on the Management of Dyslipidemia recommends the use of the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations to predict atherosclerotic cardiovascular disease (ASCVD) risk while concurrently revising previous risk-category thresholds. The impact of these reclassifications is yet to be described. Objectives The authors characterized ASCVD reclassification and statin recommendations under the 2026 guideline, evaluated clinical events under this reclassification, and examined risk enhancement with risk enhancers and coronary artery calcium (CAC) burden. Methods Adults (N = 6,098) from the MESA (Multi-Ethnic Study of Atherosclerosis) were assessed, comparing the Pooled Cohort Equations (PCE) and 2013 thresholds to PREVENT with 2026 thresholds. We evaluated the degree of directional reclassification, impact on statin recommendations, and risk enhancement with biomarkers and CAC burden. Results Over a median follow-up of 10 years, 6.0% of participants had an ASCVD event. PREVENT reclassified 16.4% to a lower and 13.1% to a higher risk category as compared to the PCE. The statin recommendation under PREVENT was 50.4% compared to 55.2% under PCE. Of those who were no longer recommended for statin use, 4.9% went on to have an event. Individuals who were reclassified downward but had elevated CAC or any risk-enhancing factors had a higher event rate. Conclusions Adherence to the 2026 guideline may lead to a small net downward reclassification of predicted ASCVD risk. Statin recommendations will fall modestly, however, not accompanied by a substantial number of subsequent events. Risk enhancers and elevated CAC identify higher risk subgroups than their PREVENT risk would suggest, emphasizing their supporting role in risk prediction.